| Gene symbol | BCL2 | Synonyms | Bcl-2, PPP1R50 | Type of gene | protein-coding |
| Chromosome | 18 | Map location | 18q21.33 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | BCL2 apoptosis regulator | ||||
| GTO ID | GTC1211 |
| Trial ID | NCT00070083 |
| Disease | Lymphoma |
| Altered gene | Bcl-2 |
| Therapeutic/Target gene | Target gene |
| Therapy | ASO |
| Treatment | Genasense|G3139|oblimersen sodium |
| Co-treatment | rituximab|cyclophosphamide|doxorubicin hydrochloride|prednisone|vincristine sulfate |
| Phase | Phase1 |
| Recruitment status | Completed |
| Title | A Phase I Study Of G3139 Antisense Oligonucleotide (Oblimersen) In Combination With CHOP And Rituximab In Untreated Advanced Stage Diffuse Large B Cell Lymphoma |
| Year | 2003 |
| Country | United States|Canada |
| Company sponsor | British Columbia Cancer Agency |
| Other ID(s) | CDR0000329985|BCCA-NCI-5818|NCI-5818 |
| Vector information | |||
|
|||
| Cohort 1 | |||||
|
|||||